Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: To D or not to D: That is the question

Current Opinion in Nephrology and Hypertension

Volumn 20, Issue 4, 2011, Pages 354-359

  Moorthi, Ranjani N ^a   Kandula, Praveen ^a   Moe, Sharon M ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c OPW 526 ^*  (United States)

Author keywords

kidney; trials; vitamin D

Indexed keywords

ALFACALCIDOL; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIFEDIOL; CALCIMEDIN; CALCITRIOL; COLECALCIFEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXERCALCIFEROL; PARICALCITOL; PLACEBO; VITAMIN D; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; FALL RISK; FRACTURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INSULIN RESISTANCE; MICROALBUMINURIA; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

CALCITRIOL; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 79958833543     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3283470450     Document Type: Review

References (48)

1. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009; 19:73-78.
2. Rosen CJ. Clinical practice vitamin D insufficiency. N Engl J Med 2011; 364:248-254.
3. KDIGO. Clinical practice guidelines for the management of CKD-MBD. Kidney Int 2009; 76:S1-S130. A systematic review of treatment studies of vitamin D therapies in CKD patients.
4. Palmer SC, McGregor DO, Craig JC, et al. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; 4:CD008175.
5. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357:266-281.
6. Academies IoMotN. Dietary reference intakes for calcium and vitamin D. Institute of Medicine of the National Academies; 2010.
7. Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009; 169:626-632.
8. Bhan I, Burnett-Bowie SA, Ye J, et al. Clinical measures identify vitamin D deficiency in dialysis. Clin J Am Soc Nephrol 2010; 5:460-467.
9. Tolouian R, Rao DS, Goggins M, et al. Seasonal variation of vitamin D in patients on hemodialysis. Clin Nephrol 2010; 74:19-24.
10. LaClair RE, Hellman RN, Karp SL, et al. Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 2005; 45:1026-1033. (Pubitemid 40806515)
11. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71:31-38. (Pubitemid 44967731)
12. Jones G. Why dialysis patients need combination therapy with both cholecalciferol and a calcitriol analog? Semin Dial 2010; 23:239-243.
13. Barreto DV, Barreto FC, Liabeuf S, et al. Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:1128-1135.
14. Mehrotra R, Kermah DA, Salusky IB, et al. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int 2009; 76:977-983.
15. Wolf M, Shah A, Gutierrez O, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 2007; 72:1004-1013. (Pubitemid 47530570)
16. Boudville N, Inderjeeth C, Elder GJ, Glendenning P. Association between 25-hydroxyvitamin D, somatic muscle weakness and falls risk in end-stage renal failure. Clin Endocrinol (Oxf) 2010; 73:299-304.
17. Bischoff-Ferrari HA, Dawson-Hughes B, Staehelin HB, et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 2009; 339:843-846.
18. Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: a meta-analysis of randomized controlled trials. Arch Intern Med 2009; 169:551-561.
19. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303:1815-1822.
20. Garcia-Canton C, Bosch E, Auyanet I, et al. 25 Hydroxyvitamin D levels and cardiovascular risk in a cohort of patients with advanced chronic kidney disease. Nefrologia 2010; 30:435-442.
21. Stefikova K, Spustova V, Krivosikova Z, et al. Insulin resistance and vitamin D deficiency in patients with chronic kidney disease stage 2-3. Physiol Res 2011; 60:149-155.
22. Petchey WG, Howden EJ, Johnson DW, et al. Cardiorespiratory fitness is independently associated with 25-hydroxyvitamin D in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6:512-518.
23. Kandula P, Dobre M, Schold JD, et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6:50-62.
24. Oksa A, Spustova V, Krivosikova Z, et al. Effects of long-term cholecalciferol supplementation on mineral metabolism and calciotropic hormones in chronic kidney disease. Kidney Blood Press Res 2008; 31:322-329.
25. Chandra P, Binongo JN, Ziegler TR, et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 2008; 14:10-17.
26. Dogan E, Erkoc R, Sayarlioglu H, et al. Effect of depot oral cholecalciferol treatment on secondary hyperparathyroidism in stage 3 and stage 4 chronic kidney diseases patients. Ren Fail 2008; 30:407-410. (Pubitemid 351868693)
27. K/DOQI NKF. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42:S1-S201.
28. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute ofMedicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96:53-58.
29. Moe SM. Vitamin D, cardiovascular disease, and survival in dialysis patients. J Bone Miner Res 2007; 22 (Suppl 2):V95-V99. (Pubitemid 351304658)
30. Shoben AB, Rudser KD, de Boer IH, et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19:1613-1619.
31. Ogawa T, Ishida H, Akamatsu M, et al. Relation of oral 1alpha-hydroxy vitamin D3 to the progression of aortic arch calcification in hemodialysis patients. Heart Vessels 2010; 25:1-6.
32. De Boer IH, Ioannou GN, Kestenbaum B, et al. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2007; 50:69-77. (Pubitemid 46962855)
33. Inukai T, Fujiwara Y, Tayama K, et al. Alterations in serum levels of 1 alpha,25(OH)2 D3 and osteocalcin in patients with early diabetic nephropathy. Diabetes Res Clin Pract 1997; 38:53-59. (Pubitemid 27428468)
34. Verrotti A, Basciani F, Carle F, et al. Calcium metabolism in adolescents and young adults with type 1 diabetes mellitus without and with persistent microalbuminuria. J Endocrinol Invest 1999; 22:198-202. (Pubitemid 29158639)
35. Zhang Z, Sun L, Wang Y, et al. Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 2008; 73:163-171.
36. Freundlich M, Quiroz Y, Zhang Z, et al. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74:1394-1402.
37. Szeto CC, Chow KM, Kwan BC, et al. Oral calcitriol for the treatment of persistent proteinuria in immunoglobulin A nephropathy: an uncontrolled trial. Am J Kidney Dis 2008; 51:724-731. (Pubitemid 351626254)
38. Alborzi P, Patel NA, Peterson C, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52:249-255.
39. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68:2823-2828. (Pubitemid 43251029)
40. Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54:647-652.
41. De Zeeuw D, Agarwal R,Amdahl M, et al. Selective vitaminDreceptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376:1543-1551.
42. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab 2001; 86:1633-1637. (Pubitemid 32377290)
43. Thadhani R, Appelbaum E, Chang Y, et al. Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol 2011; 33:139-149.
44. Mittman N, Desiraju B, Meyer KB, et al. Treatment of secondary hyperparathyroidism in ESRD: a 2-year, single-center crossover study. Kidney Int Suppl 2010; S33-S36.
45. Vulpio C, Maresca G, Distasio E, et al. Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: responsiveness is related to parathyroid gland size. Hemodial Int 2011 [Epub ahead of print].
46. Kiattisunthorn K, Moe SM. Chronic kidney disease-mineral bone disorder (CKD-MBD). Int Bone Miner Soc IBMS-BoneKey 2010; 7.
47. Hansen D, Brandi L, Rasmussen K. Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol. BMC Nephrol 2009; 10:28.
48. Moe SM, Saifullah A, LaClair RE, et al. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol 2010; 5:299-306.